51.50
-0.06
(-0.12%)
After Hours: 51.51
+0.01
(0.03%)
May 20, 4:42PM EDT
NYSE
real-time data -
Disclaimer
Currency in USD
| Range | 51.42 - 51.77 |
| 52 week | 39.72 - 52.27 |
| Open | 51.52 |
| Vol / Avg. | 2.96M/1.86M |
| Mkt cap | 64.36B |
| P/E | 11.41 |
| Div/yield | 1.90/5.44 |
| EPS | 4.52 |
| Shares | 1.25B |
| Beta | 0.61 |
| Inst. own | 9% |
Events
Apr 25, 2013
Q1 2013 AstraZeneca PLC Earnings Conference Call
Apr 22, 2013
AstraZeneca PLC at Biotechnology Industry Organization (BIO) International Convention
Mar 21, 2013
AstraZeneca PLC Capital Markets Day -
Mar 11, 2013
AstraZeneca PLC at Edison Electric Institute International Utility Conference
Mar 11, 2013
AstraZeneca PLC at EBD BIO-Europe Spring
Feb 25, 2013
AstraZeneca PLC at Citi Global Healthcare Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 15.85% | 22.62% |
| Operating margin | 21.88% | 29.13% |
| EBITD margin | - | 48.06% |
| Return on average assets | 7.67% | 11.90% |
| Return on average equity | 17.62% | 26.81% |
| Employees | 51,700 | - |
| Carbon Disclosure Rating | - | 73/100 |
Address
2 Kingdom Street, Paddington
LONDON, ENG W2 6BD
United Kingdom - Map
+44-20-76048000 (Phone)
+44-20-76048151 (Fax)
LONDON, ENG W2 6BD
United Kingdom - Map
+44-20-76048000 (Phone)
+44-20-76048151 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca�s products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. In August 2012, Alliance Pharma plc�s subsidiary, Alliance Pharmaceuticals Limited, acquired the antimalarial brands. In August 2012, the Company announced the acquisition of Amylin Pharmaceuticals, Inc. by Bristol-Myers Squibb Company.
Officers and directors
| Pascal Soriot | Chief Executive Officer, Executive Director | |
| Simon Jonathan Lowth | Chief Financial Officer, Executive Director | |
| Lynn Tetrault | Executive Vice President - Human Resources and Corporate Affairs | |
| Ruud Dobber | Executive Vice President, Europe | |
| Marc Dunoyer | Executive Vice President, Global Portfolio & Product Strategy | |
| Paul Hudson | Executive Vice President, North America | |
| Bahija Jallal Ph.D. | Executive Vice President, MedImmune | |
| Mark Mallon | Executive Vice President, International | |
| Briggs Morrison | Executive Vice President - Global Medicines Development | |
| Menelas Pangalos | Executive Vice President - Innovative Medicines |